Press Release

H1N1 Vaccines Market to Grow with a CAGR of 4.23% through 2028

Technological advancements, and the ever-present threat of influenza outbreaks are expected to drive the Global H1N1 Vaccines Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “H1N1 Vaccines Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global H1N1 Vaccines Market stood at USD 9910.85 million in 2022 and is anticipated to grow with a CAGR of 4.23% in the forecast period, 2024-2028. This can be attributed to collaboration and international cooperation. International organizations, such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI), have played a critical role in coordinating global efforts to combat influenza. Collaboration among countries and organizations has facilitated vaccine research, development, and equitable distribution.


Furthermore, antigen-sparing strategies may gain traction, particularly during vaccine shortages or in the event of an H1N1 pandemic. These approaches aim to increase the number of vaccine doses produced from a limited antigen supply, ensuring more widespread coverage.


The H1N1 virus, commonly referred to as swine flu, is an infectious ailment in humans caused by the swine H1N1 virus. This virus manifests with symptoms such as persistent cough, cold, high fever, red watery eyes, body aches, headaches, and a general sense of discomfort. It has the capacity to affect various species, including swine, birds, horses, and other animals. The H1N1 virus is highly contagious and can be transmitted widely through small droplets of saliva released during coughs or sneezes of infected individuals. It primarily inflicts damage on the respiratory system, affecting the nose, lungs, and throat. This virus is categorized as an RNA virus within the Orthomyxoviridae family. Notably, in 2009, a strain of swine flu named "H1N1" swept across the globe.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global H1N1 Vaccines Market.”


As per information from the World Health Organization (WHO), on an annual basis, there are approximately 3 to 5 million instances of severe illness attributed to seasonal influenza, resulting in an estimated 290,000 to 650,000 respiratory-related deaths. In developed nations, the majority of influenza-related fatalities occur in individuals aged 65 and above. The spectrum of seasonal influenza illnesses varies from mild to severe, and in some cases, it can be fatal.


The H1N1 vaccines market is being driven by several factors in the business landscape, including the escalating incidence of epidemic H1N1 infections, diminishing immunity among the elderly population, and advancements in vaccine technology.


The Global H1N1 Vaccines Market is segmented into route of administration, type of brand, distribution channel, regional distribution, and company.

Based on its distribution channel, Hospital pharmacies are poised to dominate the Global H1N1 Vaccines Market for several compelling reasons. Firstly, hospitals are strategically positioned as healthcare hubs that cater to a wide spectrum of patients, including those in high-risk groups. This ensures a substantial and consistent demand for H1N1 vaccines. Secondly, hospital pharmacies possess the necessary infrastructure and expertise to store and administer vaccines efficiently, adhering to stringent regulatory standards. This instills confidence in patients and healthcare providers alike, boosting the credibility of hospital pharmacies as reliable sources for vaccination. Additionally, hospitals often collaborate with government health agencies and insurance providers, facilitating wider access and affordability for patients. This, in turn, further solidifies their dominance in the H1N1 vaccines market. Lastly, hospitals can leverage their established healthcare networks to conduct outreach and vaccination campaigns, driving greater vaccination coverage and ultimately exerting a significant influence over the market's dynamics.


Based on region, North America commands a substantial market share in the H1N1 vaccines sector, and this trend is expected to persist during the forecast period. This expectation is rooted in the region's proactive governmental efforts to prevent H1N1 infections and its well-developed research infrastructure. As per data from the Centers for Disease Control (CDC), roughly 8 percent of the U.S. population falls ill with influenza, leading to approximately 31.4 million doctor visits and 200,000 hospitalizations during each flu season. Furthermore, ongoing technological advancements in the field of vaccines, coupled with the presence of a robust healthcare infrastructure, are acting as catalysts for significant growth in the overall regional market.


Major companies operating in Global H1N1 Vaccines Market are:

  • AstraZeneca PLC
  • Sanofi Pasteur MSD AG
  • GSK PLC
  • Abbott Laboratories Inc
  • CSL Ltd
  • Pfizer Inc
  • CPL Biologicals Pvt Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Sinovac Biotech Co Ltd
  • Zydus Lifesciences Ltd


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The global H1N1 vaccines market is poised for significant developments as it responds to emerging trends in vaccine technology, surveillance, and pandemic preparedness. Universal vaccines, mRNA technology, personalized medicine, and digital solutions are reshaping the landscape, promising more effective prevention and control of H1N1 influenza. As these trends continue to evolve, collaboration among governments, pharmaceutical companies, and public health organizations will be key to realizing the full potential of these advancements and ensuring a safer and healthier future for all,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.


H1N1 Vaccines Market By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines), By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global H1N1 Vaccines Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global H1N1 Vaccines Market.


Contact

TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com

Relevant News